RECURRENT INDOLENT ADULT NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT INDOLENT ADULT NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT INDOLENT ADULT NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT INDOLENT ADULT NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Early trial probes new drug cocktail for Tough-to-Treat lymphomas
Disease control OngoingThis early-stage study is testing the safety and best dose of a three-drug combination for patients with follicular or marginal zone lymphoma that has come back or not responded to prior treatment. The drugs—venetoclax, lenalidomide, and rituximab hyaluronidase—work together to h…
Matched conditions: RECURRENT INDOLENT ADULT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug combo tested to fight tough blood cancers
Disease control OngoingThis study is testing if adding a new drug called selinexor to the standard chemotherapy regimen (RCHOP) is safe and more effective for treating B-cell non-Hodgkin's lymphoma. It will first find the safest dose of the combination, then see how well it works for newly diagnosed pa…
Matched conditions: RECURRENT INDOLENT ADULT NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC